Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05365789
Other study ID # ST-21-U58
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 20, 2022
Est. completion date March 31, 2023

Study information

Verified date October 2023
Source Church & Dwight Company, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will evaluate the safety and efficacy of the study medical device plus standard of care versus standard of care in subjects between 3 and 48 months (inclusive) presenting symptoms of a common cold.


Description:

The purpose of the present study is to test the efficacy, safety and tolerability of a product in relieving the symptoms of the common cold in children. This nasal spray is specifically studied for small children, classified as medical devices and is already on the market. Sterimar Blocked Nose Baby (CDEU048-28) nasal spray is a medical device and is a 100 ml bag-on-valve spray. The spray contains hypertonic solution based on 100% natural sea water rich of marine trace elements with added manganese and copper. 220 subjects will be included in this open label, randomized, parallel group, study product and standard of care versus standard of care study. Study product will be used as 1 to 2 sprays per nostril (each "dose" is 1 or 2 sprays per nostril, the second spray only if needed), for a minimum of 2 times (morning and evening) and, as needed, up to a maximum of 6 times per day (i.e., maximum 12 sprays per nostril each day). The 10 day study consists of 4 visits- Day 0 onsite, Days 3 and 6 telephone contact, and Day 10 onsite. There will be 3 strata according to age: (3-12 months), (13-24 months) and (25-48 months). Every effort will be made to ensure at least 20% of subjects in each of the study groups are 3-12 months of age.


Recruitment information / eligibility

Status Completed
Enrollment 220
Est. completion date March 31, 2023
Est. primary completion date March 31, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 3 Months to 48 Months
Eligibility Inclusion Criteria: 1. Male and female infants and toddlers. 2. Aged 3 - 48 months (inclusive) at enrolment (Day 0). 3. Parent/legal guardian answering "yes" to the question "Do you feel that your child has a cold?" at enrolment. 4. Subjects with symptoms started not later than 48 hours prior to enrolment (Day 0). 5. Subjects with nasal congestion (blocked / stuffy nose) rated as at least score of 2 (moderately bothersome) on a 0 to 3-point scale, based on morning evaluation (within an hour of child awakening). 6. Subjects showing at least one of the following additional signs of cold symptoms: runny nose, nasal crust (dry mucus), thick mucus, sneezing and cough. 7. Parent/legal guardian of the subject has given freely and expressly her/his informed consent. 8. Parent/legal guardian is cooperative and aware of the necessity and duration of the controls so that perfect adhesion to the protocol established by the clinical trial center could be expected. Exclusion Criteria: 1. Subjects presenting an oral temperature greater than 38°C at enrolment (Day 0). 2. Subjects presenting any secondary infection (such as bronchitis, otitis, tracheitis, pneumonia, etc.) at enrolment (Day 0). 3. Subjects with positive results on a streptococcal antigen screening test (rapid antigen detection test or RADT) at inclusion. 4. Subjects with a history of allergic rhinitis 5. Subjects presenting any congenital or chronic disease that in the opinion of the Investigator would adversely affect the results of the study (e.g. asthma, pneumonia, laryngotracheobronchitis, sinusitis, etc). 6. Subjects presenting any kind of immunodeficiency. 7. Subjects presenting any hypersensitivity or allergy or intolerance to any component of the study products or of the rescue medication (paracetamol) 8. Subjects with a positive medical history to any significant illness within the 2 weeks prior to the enrolment (Day 0). 9. Subjects presenting any active systemic infection or medical condition that may require treatment or therapeutic intervention during the study. 10. Subjects currently participating or having participated in another clinical trial during the last 30 days prior to enrolment (Day 0). 11. Subjects using saline nose drops or nasal sprays or pumps other than the study products, antibiotics, antivirals, intranasal medicines, decongestants, antihistamines, echinacea, combination cold formulas, supplements containing = 10 mg zinc that would influence symptoms scores at enrolment (Day 0) within 12 hours prior the day of screening 12. Subject who was abroad in a country with a higher incidence rate of Covid-19 than Poland, within 14 days before the beginning of the study. 13. Subject who have had contact with any person infected with COVID-19 within 10 days before the beginning of the study. 14. Subject who are currently home quarantined, as recommended by the Sanitary Inspection.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Blocked Nose Baby nasal spray
One or two nasal sprays will be administered to each nostril for a minimum of 2 times per day up to a maximum of 6 times per day for a maximum of 10 days.
Other:
Standard of care
Standard of care consists of hydration, rest at home and antipyretic paracetamol as necessary.

Locations

Country Name City State
Poland PRIVATE PRACTICE ul. Osiedle Sierakowskich 5 Sztum

Sponsors (1)

Lead Sponsor Collaborator
Church & Dwight Company, Inc.

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Other Onset of relief Assessment of onset of relief (immediate relief) after the entire product application is completed (1 or 2 sprays) at Day 0 (baseline) and daily from Day 1 to Day 3 of the study; within investigational device group.
the study.
assessed at 5, 15, and 30 minutes post first application of device every morning from Day 0 to 3
Other Concomitant medications Assessment of use of concomitant medications (frequency, excluding paracetamol) will be done from the beginning to the end of the study; comparisons between groups. Through study completion, an average of 10 days.
Other Frequency of paracetamol administration. Assessment of use of paracetamol (frequency) will be done from the beginning to the end of the study; comparisons between groups. Through study completion, an average of 10 days.
Other Quality of sleep. Assessment of quality of sleep will be evaluated by means of a questionnaire ("Quality of Sleep Questionnaire"), on a 0 to 3-point scale, with higher score indicating a worse outcome, with 0=not at all, 1=slightly, 2=moderately and 3=severely, to be completed from Day 0 (baseline) and daily from the beginning to the end of the study; comparisons between groups. Through study completion, an average of 10 days.
Other Global assessment on common cold status. Global assessment on common cold status will be evaluated by means of the "Global Assessment on Common Cold Status Questionnaire", on a 0 to 3-point scale, with higher score indicating a better outcome, with 0=no relief at all, 1=slight relief, 2=moderate relief and 3=complete relief, to be completed from the beginning to the end of the study; comparisons between groups. Through study completion, an average of 10 days.
Primary Change of nasal congestion Assess reduction of nasal congestion, evaluated by means of a specific questionnaire ("Cold Symptom Severity Questionnaire") on a 0 to 3-point scale, with higher score indicating a worse outcome, with 0 =not at all, 1=mild, 2=moderate and 3=severe to be completed at Day 0 (baseline) and daily from the beginning to the end of the study; comparisons between groups. Through study completion, an average of 10 days.
Secondary Change of other cold symptoms Assess change of other cold symptoms, evaluated by means of a specific questionnaire ("Cold Symptom Severity Questionnaire"),on a 0 to 3-point scale, with higher score indicating a worse outcome, with 0=not at all, 1=mild, 2=moderate and 3=severe, to be completed at Day 0 (baseline) and daily from the beginning to the end of the study; comparisons between groups.
Other cold symptoms: Stuffy nose, Nasal crust, Runny nose, Thick mucus, Sneezing, Cough
Through study completion, an average of 10 days.
Secondary Occurrence of secondary infections Assessment of occurrence of secondary infections (number) daily, from the beginning to the end of the study; comparison between groups. Secondary infections will be confirmed by the Investigator. Through study completion, an average of 10 days.
See also
  Status Clinical Trial Phase
Completed NCT00665977 - Effect of Heated Humidity With Thermosmartâ„¢ Compared to an Intranasal Steroid in Improving Compliance and Nasal Symptoms in Patients Using Continuous Positive Airway Pressure Phase 3
Completed NCT05843071 - PMCF Study to Evaluate Performance and Safety of "NASAL SPRAYS " Used to Relieve Nasal Congestion and Dryness N/A
Completed NCT00957996 - Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza Phase 3
Completed NCT00829634 - Steady State Kinetics of l-Methamphetamine and Validation of Sensitivity of Dose Estimation N/A
Completed NCT00662337 - Bioequivalence Between Two Oral Formulations of Diphenhydramine Hydrochloride Phase 1
Completed NCT05247333 - Implementation of a Minor Ailment Service in Community Pharmacy Practice N/A
Recruiting NCT05244148 - Two Seawater-based Formulations for Relief of Nasal Congestion in Paediatric Subjects N/A
Completed NCT05159271 - Efficacy and Safety of Azeol Nasal Spray Versus Placebo in the Treatment of Early Symptoms of Common Cold in Adults N/A
Completed NCT02113449 - Market Potential of Carbon Dioxide Nasal Spray Phase 2
Terminated NCT00958776 - A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza Phase 3
Completed NCT00648973 - To Determine if Diphenhydramine Works for Nasal Congestion at Two Different Doses Phase 4
Completed NCT03399721 - Investigation of Kinetic Oscillation Stimulation by the Chordate System S101 in the Treatment of Non Allergic Rhinitis N/A
Completed NCT01354418 - Bioequivalence of Single Dose Phenylephrine Extended Release Tablets and Phenylephrine HCl Immediate Release Tablets Dosed Every Four Hours (P08340)(COMPLETED) Phase 1
Completed NCT04797936 - BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19 Phase 4
Completed NCT03906968 - The Safety and Efficacy of a SinuSonic Intervention N/A
Completed NCT02100605 - Study on Hypertonic Saline Nasal Spray N/A
Recruiting NCT06323304 - Efficacy and Safety of Auricular Acupressure in Treating Allergic Rhinitis N/A
Withdrawn NCT04790487 - Chlorpheniramine Maleate Nasal Spray for Chronic Rhinitis Phase 2/Phase 3
Completed NCT01448057 - Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu Phase 3
Completed NCT01129765 - Home Usability of a Nasal Lavage System in Children N/A